We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Cannabinoid Technologies Holdings Plc | LSE:OCTP | London | Ordinary Share | GB00BMVMRB86 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.75 | 1,054,951 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.70 | 0.80 | 0.75 | 0.75 | 0.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | -5.95M | -0.0062 | -1.21 | 7.2M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:49:51 | O | 500,000 | 0.7144 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 14/11/2023 | 07:00 | UKREG | Oxford Cannabinoid Tech.Holdings Directorate Appointment |
| 24/10/2023 | 06:05 | UKREG | Oxford Cannabinoid Tech.Holdings TR-1: Notification of major holdings |
| 20/10/2023 | 08:37 | ALNC |  IN BRIEF: Kingsley Capital reduces stake in Oxford Cannabinoid |
| 20/10/2023 | 06:05 | UKREG | Oxford Cannabinoid Tech.Holdings TR-1: Notification of major holdings |
| 20/10/2023 | 06:04 | UKREG | Oxford Cannabinoid Tech.Holdings Director Dealing |
| 10/10/2023 | 10:34 | ALNC | Oxford Cannabinoid completes Phase 1 study for lead asset OCT461201 |
| 10/10/2023 | 06:00 | UKREG | Oxford Cannabinoid Tech.Holdings Phase I Clinical Trial Results |
| 29/9/2023 | 06:00 | UKREG | Oxford Cannabinoid Tech.Holdings Result of AGM |
| 25/9/2023 | 09:41 | ALNC | Oxford Cannabinoid issues final dose of lead pharmaceutical asset |
| 25/9/2023 | 06:00 | UKREG | Oxford Cannabinoid Tech.Holdings Final Dose Administered |
Oxford Cannabinoid Techn... (OCTP) Share Charts1 Year Oxford Cannabinoid Techn... Chart |
|
1 Month Oxford Cannabinoid Techn... Chart |
Intraday Oxford Cannabinoid Techn... Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/10/2023 | 06:15 | Oxford cannabinoid technologies | 428 |
| 21/5/2023 | 19:07 | Oxford cannabinoid with charts | 490 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2023-12-07 15:49:53 | 0.71 | 500,000 | 3,572.00 | O |
| 2023-12-07 15:31:45 | 0.78 | 1,656 | 12.99 | O |
| 2023-12-07 15:23:49 | 0.71 | 25,558 | 182.59 | O |
| 2023-12-07 15:05:38 | 0.78 | 23,981 | 188.11 | O |
| 2023-12-07 14:44:51 | 0.70 | 1,958 | 13.71 | O |
| Top Posts |
|---|
Posted at 07/12/2023 08:20 by Oxford Cannabinoid Techn... Daily Update Oxford Cannabinoid Technologies Holdings Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker OCTP. The last closing price for Oxford Cannabinoid Techn... was 0.75p.Oxford Cannabinoid Techn... currently has 960,415,644 shares in issue. The market capitalisation of Oxford Cannabinoid Techn... is £7,203,117. Oxford Cannabinoid Techn... has a price to earnings ratio (PE ratio) of -1.21. This morning OCTP shares opened at 0.75p |
Posted at 24/10/2023 06:15 by burtond1 A plants beauty lies in its leaves, but its strength lies in its roots."...I am excited to be buying more #OCTP personally. Given the recent Phase I results, the Company appears to me to be significantly undervalued. It is for this reason that I, along with other shareholders and employees of Kingsley, have chosen to increase our direct holding in the business..."https://to |
Posted at 20/10/2023 07:39 by burtond1 Good news this for #OCTP and a massive vote of confidence...Kingsle |
Posted at 10/10/2023 09:59 by sep800 Nice to received a positive RNS this morning as expected. Phase 2 onwards and upwards.Markets will soon wake up to OCTP |
Posted at 29/9/2023 14:06 by sep800 Very quite on here lately. Not long for confirmation of phase 1 complete. I think we have been hinted that no adverse effect therefore expecting phase 2 fairly soon. Been a long road since IPO and the share price needs some recovery. However at this level take advantage of the very low current share price Funded till next April 2024 and expect a JV or share offer to existing shareholders at a much higher level than currently. Plenty other products in the pipeline and I would expect OCTP would be a great performer during 2024.GLA |
Posted at 14/9/2023 06:21 by burtond1 Capital Re-Organisation Questions..Does this help. This is the way i see it... It's a purely a procedural process allowing the Company to reduce the nominal value of its shares from 1p to 0.1p WITHOUT diluting existing shareholders as the Companies Act prohibits companies from issuing shares at below the nominal value. It'll have ZERO impact on shareholders - no new ordinary shares are being issued. The reason for it is to allow the company to take advantage of the general authority to issue new shares (up to 20% of share capital only) it's requesting at the AGM - that means the Company is able to be more agile as and when it wants to raise some cash. This is all subject to a shareholder vote at the AGM so is entirely in shareholder control. There's no impact on existing warrants currently issued by the company, which have a 5p/share exercise price. There's nothing fishy going on! Amy more thoughts or questions please send to me and i can try and pass on to the BOD if thats helps? david burton.tms@gmail.com |
Posted at 28/7/2023 23:05 by sep800 OCTP about to turn heads with its trials, They are still on for results Q3. Once the news confirms the drug is safe and without serious side effects it will roll on to Phase 2.This phase 1 results will surge OCTP closer to being one of those rare successful Pharmaceutical companies that their R&D actually pays dividends. @ £9M M/C will be long gone. Glad to be on board at such an early stage of success. Plenty news flow to follow. We are also seeing the price being suppress for some large buy orders, most sells are buys and with 2x 6M and 2M recent buys shows confidence. I just can't see the share price going down any further especially with recent Videos and announcements. MM's will have to let this go GLA |
Posted at 10/7/2023 15:22 by sep800 If you have researched properly what company you decide to invest in then OCTP has all the products to be fruitful. OCTP is not for day trading at this stage, nevertheless there are opportunities when the share price has fallen well below the value of a company that one should consider a time to buy or top-up. At this level it's a buy, especially with news of its phase 1 trials due. OCTP do not need to raise and still have £5M cash and are fully funded for its trials and research till 2024.All to their own, but patients will be rewarded. Buy, leave in a bottom drawer and come back next year, or trade on news GL |
Posted at 05/1/2023 15:44 by sep800 OCTP have come along way since the IPO 18 months ago, And the markets at that time 5p was a sensible value. Since then OCTP have incurred the usual drop in the share price due to lack of activity as most companies sort their admin out in the first 12 months together with the markets shorting the share price as a safe calculated risk due to the given factors.However £0.005p was well over done and the Markets have now u-turned as OCTP gain advantages from its trials with a product well known to the medical industry. We are now going to see the share price raise to a more suitable level especially given the commencement of the trials, With £5M cash which means no fund raising this year. We have so much news to follow very soon and with OCTP on track to deliver a product this year, I see no reason why the share price short term to be 2.5p-3p moving up on further positive news. Certainly plenty of up side from here and one to hold onto at least prior to results. Any positive news will accelerate the share price northwards and with just A small amount of free float shares available, the share price will rise quickly just as we have seen in the last week. I believe the MM's got caught out last week and are trying to force sellers to balance their books, however if there are no sellers to share price will keep rising. Either way I believe we are in a good position ready for any positive news to land. GLA |
Posted at 05/1/2023 15:37 by sep800 OCTP have come along way since the IPO 18 months ago, And 5p was a sensible value. Since then OCTP have incurred the usual drop in the share price due to lack of activity as most companies sort their admin out in the first 12 months together with the markets shorting the share price as a safe calculated risk due to the given factors.However £0.005p was well over done. As OCTP gain advantages from its trials with a product well known to the medical industry,We are now going to see the share price raise to a more suitable level especially given the commencement of the trials together with £5M cash which means no fund raising this year. So much news to follow and on track to deliver a product this year, I see no reason way the share price short term be 2.5p-3p moving up on further positive news. Certainly plenty of up side from here and one to hold onto at least prior to results. Any positive news will accelerate the share price northwards with small amount of free float shares available, the share price will rise quickly just as we have seen in the last week. I believe the MM's got caught out last week and are trying to force sellers to balance their books, however if there are no sellers to share price will keep rising. Get ready for positive news to land. GL |
Posted at 12/12/2022 07:57 by manual dexterity Oxford Cannabinoid Tech.Holdings Trading Update12/12/2022 7:00am UK Regulatory (RNS & others) Oxford Cannabinoid Techn... (LSE:OCTP) Intraday Stock Chart Monday 12 December 2022 Click Here for more Oxford Cannabinoid Techn... Charts. TIDMOCTP RNS Number : 2871J Oxford Cannabinoid Tech.Holdings 12 December 2022 Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the "Company") Trading Update Continued progress, commencement of clinical trials of lead drug candidate imminent Financial and operational targets remain on track and on budget Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market, announces a positive trading and operational update for the six months ended 31 October 2022 ("the Period"). Financial Highlights The budget review, announced on 26 August 2022, realigned the Company's development and expenditure programme to focus on bringing the Company's lead compound, OCT461201, through Phase I clinical trials. Taking this action meant that funds, which would otherwise have been fully utilised by April 2023, are now expected to extend to Q4 2023. Importantly, the Company remains on track and on budget to commence clinical trials for OCT461201 in January 2023, with publication of its interim results for the period ended 31 October 2022 also anticipated in January 2023. During the Period, the Group incurred c.GBP3.1 million of R&D costs, with progress being made on all four programmes. As at 31 October 2022, OCTP and its subsidiary, Oxford Cannabinoid Technologies Ltd. ("OCT"), (together, "the Group") had total cash reserves of approximately GBP5 million and remained debt free. Operational update Operational progress has been consistent with the Board's expectations and the Board remains confident that OCTP will achieve the milestones set out in its current development timeline. Work under the Group's GBP2.6 million contract research agreement with Aptuit (Verona) SRL, a subsidiary of Evotec SE (together "Evotec"), which commenced in July 2021 is now almost complete. Evotec will provide the Company with a submission-ready regulatory document by the end of December 2022 and will deliver an approved batch of drug product to the OCT461201 Programme 1 Phase I clinical trial unit during Q1 2023. In addition to the progress made on OCT461201, pre-clinical work for OCT130401 is almost complete, ensuring that Programme 2 will be Phase I ready in early 2023 at which time further development will be placed on hold in order to preserve cash. Development work for Programmes 3 and 4 has also continued, with the Company still on target to be at pre-clinical stage (for programme 3) and lead stage (for programme 4) with these programmes by Q2 2023. Clarissa Sowemimo-Coker, Interim CEO of OCTP, said: " We are incredibly pleased with the ongoing progress and the fact that we remain on track to meet our financial and operational targets. This is a big achievement and is testament to the adaptability, skill, and "can do" attitude of Dr Valentino Parravicini, his team, and our external partners. "As OCTP nears a critical juncture in its journey to introduce prescription cannabinoid medicines to the US$ multi-billion pain market, we are carefully managing cash and are well placed to deliver on our key objectives. I look forward to updating the market on our continued progress with the half-year results." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company accept responsibility for the content of this announcem |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
